Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping

Patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping can benefit from crizotinib treatment. Currently, the main resistance mechanisms to crizotinib are MET D1228N and Y1230C mutations. We reported a case of a Chinese NSCLC patient with MET exon 14 skipping detected by targ...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Biol Ther
Hlavní autoři: Ding, Guanggui, Wang, Jian, Ding, Peikun, Wen, Yuxin, Yang, Lin
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2019
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606013/
https://ncbi.nlm.nih.gov/pubmed/30744539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1566049
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky